(MM) (QCOR) Quote

Selloff down to the teens due to Achtar dropped coverage fiasco 2 years ago, and nice climb back up to 90s thanks to Andrew Left and Citron Research. He'll have a tough time thrashing Achtar now that its owned by Mallinckrodt behemoth. But the short squeeze on this stock with over 100% institutional ownership was sorta weird.

Mallinckrodt Completes Acquisition Of Questcor Pharmaceuticals

- Creates a diversified, high-growth therapeutic portfolio, capable of delivering substantial, sustainable value for shareholders- Significantly increases Mallinckrodt's scale, revenues, profitability and cash flow- Expected to be immediately accretive to Mallinckrodt's fiscal 2014 adjusted diluted earnings per share; significantly accretive to adjusted diluted earnings per share in fiscal 2015

DUBLIN, Aug. 14, 2014 /PRNewswire/ -- Mallinckrodt plc MNK +1.82% , a leading global specialty pharmaceutical company, today announced that it has completed its acquisition of Questcor Pharmaceuticals, Inc. QCOR +1.65% in a cash and stock transaction valued at approximately $5.8 billion. The acquisition is expected to be immediately accretive to Mallinckrodt's fiscal 2014 adjusted diluted earnings per share and significantly accretive to its adjusted diluted earnings per share in fiscal 2015.

The merger follows strong approval by both Mallinckrodt and Questcor shareholders at separate special meetings held today. Under the terms of the merger agreement, Questcor shareholders will receive $30.00 in cash and 0.897 of a Mallinckrodt ordinary share for each Questcor share.

"We are pleased to complete this transformative transaction and believe it will provide a strong, durable, well-diversified and sustainable platform, capable of generating significant future revenue and earnings growth for Mallinckrodt shareholders," said Mark Trudeau, President and Chief Executive Officer of Mallinckrodt. "HP Acthar® Gel has demonstrated success in treating patients suffering from a variety of devastating and difficult-to-treat autoimmune and inflammatory illnesses. We are confident that Acthar will be a strong complement to Mallinckrodt's broadening portfolio of leading specialty pharmaceutical brands, and we look forward to leveraging our extensive manufacturing and scientific expertise, as well as our experience with advocacy and payer communities, to capitalize on the many opportunities it presents."

Mr. Trudeau added, "We are very pleased to welcome the Questcor team to Mallinckrodt. We are excited about our future prospects and the benefits that our collective efforts will have for patients, our investors and the communities that we serve."

As previously disclosed, commercial operations supporting HP Acthar Gel will function as a separate business within Mallinckrodt's Specialty Pharmaceuticals segment reporting to Mr. Trudeau. It will be known as the Autoimmune and Rare Diseases business within Mallinckrodt.
...
http://www.marketwatch.com/story/mallinckrodt-completes-acquisition-of-questcor-pharmaceuticals-2014-08-14

Its done. Maybe see ya on the other side.

Questcor Pharmaceuticals, Inc. [$QCOR] due diligence

bullish short squeeze

$QCOR

DD Notes ~ http://www.ddnotesmaker.com/QCOR

##### recent news/filings ~ source: finance.yahoo.com

Mon, 30 Jun 2014 22:07:14 GMT ~ Questcor And Mallinckrodt: The Good, The Bad, And The Ugly
read full: http://seekingalpha.com/article/2293805-questcor-and-mallinckrodt-the-good-the-bad-and-the-ugly?source=yahoo
*********************************************************

Mon, 30 Jun 2014 15:53:00 GMT ~ Hey Mallinckrodt, Pay Close Attention - UnitedHealth Just Slammed Questcor's Acthar
read full: http://seekingalpha.com/article/2292885-hey-mallinckrodt-pay-close-attention-unitedhealth-just-slammed-questcors-acthar?source=yahoo
*********************************************************

Thu, 26 Jun 2014 21:47:01 GMT ~ Why Small-Cap Stocks ARRIS and Questcor Have Huge Growth Potential
read full: http://www.fool.com/investing/general/2014/06/26/why-small-cap-stocks-arris-and-questcor-have-huge.aspx?source=eogyholnk0000001
*********************************************************

Wed, 25 Jun 2014 17:49:25 GMT ~ The FDA Owes Us An Answer On Questcor's Acthar
read full: http://seekingalpha.com/article/2286053-the-fda-owes-us-an-answer-on-questcors-acthar?source=yahoo
*********************************************************

Mon, 23 Jun 2014 13:00:00 GMT ~ Questcor Pharmaceuticals Closes Transaction to Acquire International Rights to Synacthen® and Synacthen® Depot
[PR Newswire] - ANAHEIM, Calif., June 23, 2014 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (QCOR) today announced that the transaction acquiring rights to Synacthen® and Synacthen® Depot from Novartis Pharma AG and Novartis AG in certain countries outside the U.S. has now closed. Available in more than forty countries for multiple indications, Synacthen (tetracosactide) is a synthetic 24 amino acid melanocortin peptide. Synacthen Depot is a depot formulation of Synacthen. The products are approved outside the U.S. for multiple indications, including certain autoimmune and inflammatory conditions as well as for diagnostic use, but have never been developed or approved for patients in the U.S. Questcor is presently engaged in pre-clinical development for Synacthen in the U.S. "As a leader in melanocortin peptide therapeutics, we now have the opportunity with Synacthen to expand our commercial presence to more than forty international markets, and develop a new potential platform for international growth in this important emerging field of medicine," said Steve Cartt, Chief Operating Officer of Questcor.
read full: http://finance.yahoo.com/news/questcor-pharmaceuticals-closes-transaction-acquire-130000695.html
*********************************************************

##### chart ~ source: stockcharts.com



##### chart ~ source: eoddata.com



##### company info ~ source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/QCOR/company-info
Ticker: $QCOR
OTC Market Place: Not Available
CIK code: 0000891288
Company name: Questcor Pharmaceuticals, Inc.
Company website: http://www.questcor.com
Incorporated In: CA, USA

##### extra dd links

Edgar filings: http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000891288&owner=exclude&count=40
Latest filings: http://www.otcmarkets.com/stock/QCOR/filings
Latest financials: http://www.otcmarkets.com/stock/QCOR/financials
Latest news: http://www.otcmarkets.com/stock/QCOR/news - http://finance.yahoo.com/q/h?s=QCOR+Headlines

Major holdings: http://data.cnbc.com/quotes/QCOR/tab/8.1
Insider transactions (1): http://finance.yahoo.com/q/it?s=QCOR+Insider+Transactions
Insider transactions (2): http://www.secform4.com/insider-trading/QCOR.htm
Insider transactions (3): http://www.insidercow.com/history/company.jsp?company=QCOR

RegSho: http://www.regsho.com/tools/symbol_stats.php?sym=QCOR&search=search

DTCC: http://search2.dtcc.com/?q=Questcor+Pharmaceuticals%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information: http://www.spoke.com/search?utf8=%E2%9C%93&q=Questcor+Pharmaceuticals%2C+Inc.
Corporation WIKI: http://www.corporationwiki.com/search/results?term=Questcor+Pharmaceuticals%2C+Inc.&x=0&y=0
WHOIS: http://whois.domaintools.com/http://www.questcor.com
Alexa: http://www.alexa.com/siteinfo/http://www.questcor.com#
Corporate website internet archive: http://web.archive.org/web/*/http://www.questcor.com

Short Sales: http://www.otcmarkets.com/stock/QCOR/short-sales
Insider Disclosure: http://www.otcmarkets.com/stock/QCOR/insider-transactions
Research Reports: http://www.otcmarkets.com/stock/QCOR/research
Historical Prices: http://finance.yahoo.com/q/hp?s=QCOR+Historical+Prices
Basic Tech. Analysis: http://finance.yahoo.com/q/ta?s=QCOR+Basic+Tech.+Analysis
Company Profile: http://finance.yahoo.com/q/pr?s=QCOR+Profile
Key Statistics: http://finance.yahoo.com/q/ks?s=QCOR+Key+Statistics
Industry: http://finance.yahoo.com/q/in?s=QCOR+Industry
Insider Roster: http://finance.yahoo.com/q/ir?s=QCOR+Insider+Roster
Income Statement: http://finance.yahoo.com/q/is?s=QCOR
Balance Sheet: http://finance.yahoo.com/q/bs?s=QCOR
Cash Flow: http://finance.yahoo.com/q/cf?s=QCOR+Cash+Flow&annual
Market Watch: http://www.marketwatch.com/investing/stock/QCOR
Bloomberg: http://www.bloomberg.com/quote/QCOR:US
Morningstar: http://quotes.morningstar.com/stock/s?t=QCOR
Bussinessweek: http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=QCOR
Barchart: http://www.barchart.com/quotes/stocks/QCOR
OTC Short Report: http://otcshortreport.com/index.php?index=QCOR
Investopedia: http://www.investopedia.com/markets/stocks/QCOR/?wa=0

http://www.pennystocktweets.com/stocks/profile/QCOR

##### last known share structure ~ source: otcmarkets.com

Market Value: $5,639,764,117 a/o
Shares Outstanding: 60,977,015 a/o Mar 31, 2014
Float: Not Available
Authorized Shares: Not Available
Par Value: No Par Value

##### business description ~ source: otcmarkets.com



DD Notes ~ http://www.ddnotesmaker.com/QCOR

That's a nice bonus, sheesh.

ITEM 5.02 DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS.

On May 13, 2014, Questcor Pharmaceuticals, Inc. (the “Company”) entered into an amendment (the “Asarpota Amendment”) to the severance agreement with Rajesh Asarpota, the Company’s Senior Vice President, Chief Financial Officer. Under the Asarpota Amendment, if the proposed merger with Mallinckrodt plc and Quincy Merger Sub, Inc. is consummated and an excise tax is imposed on Mr. Asarpota as a result of any compensation or benefits provided to Mr. Asarpota in connection with the consummation of the proposed merger, the Company will pay or reimburse Mr. Asarpota an amount equal to such excise tax plus any taxes resulting from such payment or reimbursement.

Old news from February.

Citron has been attacking QCOR for a long time and is probably involved in the major shorting activity that has hit the stock repeatedly.

That new article from the "analyst firm" is simply a lawyer shopping for invidivuals who feel they've been deceived.

Looks like an analyst firm issued a couple of reports on the company's acthar drug. A law firm wrote a blog article that looks like they picked up on this analyst report.

insert-text-here

insert-text-here

insert-text-here


I'm not sure what to think about this. Any thoughts? This seems like a pretty damaging report.

You are right. They all seem to be jumping onto the bandwagon now.

Congrats QCOR on your Buyout! Nicely Done!!


Regards,
Tim

There is almost always an investigation whenever any company sells out/merges.

I don't think this has anything to do with shorts.

Just typical lawyers looking for some income using the usual lingo:
The investigation focuses on whether Questcor's Board of Directors breached their fiduciary duties to the Company's stockholders by failing to conduct a fair sales process and whether and by how much this proposed transaction undervalues the Company to the detriment of Questcor's shareholders.

"Faruqi & Faruqi, LLP Announces the Investigation of Questcor Pharmaceuticals Inc. (QCOR) Over the Proposed Sale of the Company to Mallinckrodt plc"

Sounds like the shorts are upset on their big losses. imo

So glad they get what they deserve!

80-100? Lmao.
Rather amazing when poster was spot on?... although it took a couple more years.

Congrats on the buyout QCOR shareholders!

Twas a nice run everyone.
Congrats to the longs, been in it since 1.25.

and the shorts get crushed...

Nice Roth pick here

New report out Wallstreetcounterpoint.com on QCOR

smh...Universal Commodity Corporation

QCOR -- just shorted at $57.335 average based on this report and tons before it:

http://www.citronresearch.com/wp-content/uploads/2013/12/QCOR1203-update-final.pdf

Interesting presentation at Credit-Suisse-Healthcare-Conference


http://www.earningsimpact.com/Transcript/84507/QCOR/2013-Credit-Suisse-Healthcare-Conference

Q2 2013, 177 million of Acthar sales, up 57% from the prior period.

Call transcript
http://www.earningsimpact.com/Transcript/82494/QCOR/Q2-2013-Earnings-Call

Seems like a huge jump in sales.
Net sales for the second quarter ended June 30, 2013 were $184.6 million, up 64% from $112.5 million in the second quarter of 2012.
http://ih.advfn.com/p.php?pid=nmona&article=58610511&symbol=QCOR

No wonder big a/h spike.

New all time hi 59.00 a/h s

wow

MK

bullish consolidation after breakout

wow nice sell right at the T.O.P

Got in today, hope the party isn't over

DBEN out at $46.45

was in this at 1.50 in 2007,, sold for 2.50 and now it creeps up big many years late.

And we are UP !

Big NEWS,

Yep and with excellent news

wow opened HOD $50 and closed LOD

DBEN in at $42

Yeah strange AH dip on blowout earnings. A similar thing happened after 2012 Q4 earnings report. QCOR blew away analysts EPS forcasts by .30 a share and yet the thing traded sideways for months.

You have to wonder why this stock has been in a holding pattern for 6 over months, but I guess there are still questions as to whether or not Achtar will be covered by major policies such as Aetna. Gee I wonder if Andrew Left and Citron Research is still shorting this.

Unusual AH trading after the earnings. Record April sales lifted the stock after the initial drop. It will be interesting tomorrow.

Nice results. Beat the street estimate and increased divi.

Go QCOR LONG!!! big epic spike going to happen if this goes over $32, valuation $90, earnings 26th no replay of last time going to happen, shorts will be exiting the building enmass soon, Funds are buying in big. Technicals have changed to positive. Short term $45 long term $100 plus. New VP is a buyout negotiator, $$$$

and $26 appears to be a crucial level

hard to see just how much accumulation is taking place, but keep an eye on $25-$26 price level in which we are currently in

Very quite in here. After days doing DD, I'm all in. Picked up @ $26.83. No debt and increasing revenue this stock has potential. Glta!

QCOR continuation breakout watch above 28.6

looks like another run but could use more volume

BREAKOUT WATCH for possible breakout above 28.6, no resistance in area just above.
Type: Continuation breakout from single resistance.
Target: 32.21, 13.2% Stop: 27.33, Loss: 4%, Profit/Loss ratio: 3.3 : 1 - Excellent

CURRENT PRICE 28.46, at resistance, 27.79 ± 0.81, type single, strength 1

RESISTANCE ABOVE +23.9% at 35.27 ± 1.02, type single, strength 3
+36.2% at 38.75 ± 1.12, type double, strength 7
+42.1% at 40.44 ± 1.17, type triple, strength 5

source: http://www.stockconsultant.com/consultnow/basicplus.cgi?symbol=QCOR

After all of these baseless class actions fail, I would love to see the company go after not only those Law firms for defamation, but also that shorter blog or website that I believe had some large monetary motive in contacting the firms.

big move today and I dont see any news that would have made it go up like it did

HUGE INSIDER BUYING

Ready for a run up!!!

PURCHASED
11/5/2012 55,000 shares@ 23.92 for a total of $1,315,400!!
11/2/2012 10,000 shares@ 24.17 for a total of $241,696


http://www.secform4.com/insider-trading/891288.htm

earnings did not disappoint but how about that nice call on market selling off, it's not done yet, but QCOR may still go up with positive earnings, but there are investigations/lawsuits so I honestly would be a little hesitant to continue playing with fire, that's all

there is only one stock i want to see tank and that is KCG and maybe GS

good luck to all here, hopefully nothing to serious with whatever is going on behind the scenes and may $30+ return

QCOR beats estimates! EPS of 0.91 from an estimate of 0.75. Tomorrow should be interesting.

been a helluva ride past couple days.

Looks as if today's bear raid failed hard and fast.

Look out belowwww

Rut ro

Good start for today...